Michael Berk, MD
Internal Medicine · Saint Louis, MONPI 1700802014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,050 of the $28,664 with a category attached, or 73.4%. AstraZeneca accounts for 84.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $21,840 and has fallen 97.6% since, to $526 in 2025. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $86.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Medtronic$2K
- Lilly USA, LLC$545
- Abbott$354
- AbbVie$287
- Amgen$229
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$21,05073%
- Travel & lodging$8133%
- Food & beverage$6,79524%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 185 | $24,335 |
| Medtronic | 7 | $1,690 |
| Lilly USA, LLC | 30 | $545 |
| Abbott | 18 | $354 |
| AbbVie(2 entities) | 22 | $287 |
| Amgen | 11 | $229 |
| Dexcom, Inc. | 9 | $164 |
| Novo Nordisk | 7 | $160 |
| W. L. Gore & Associates, Inc. | 2 | $136 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Novartis | 4 | $92 |
| Astellas Pharma US Inc | 5 | $82 |
| Radius Health, Inc. | 3 | $69 |
| Boehringer Ingelheim | 3 | $52 |
| Clarus Therapeutics Inc. | 2 | $48 |
| Antares Pharma, Inc. | 3 | $43 |
| GSK | 2 | $34 |
| Pfizer | 2 | $31 |
| Recor Medical Inc | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,664 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 394 | $545,661 |
| TrulicityDulaglutide | 184 | $300,928 |
| JardianceEmpagliflozin | 214 | $251,112 |
| FarxigaDapagliflozin Propanediol | 251 | $246,286 |
| OzempicSemaglutide | 147 | $223,292 |
| JanuviaSitagliptin Phosphate | 140 | $149,911 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $105,841 |
| EliquisApixaban | 117 | $95,559 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 111 | $79,809 |
| Repatha SureclickEvolocumab | 68 | $76,349 |
| Xigduo XrDapaglifloz Propaned/Metformin | 62 | $72,237 |
| TradjentaLinagliptin | 77 | $70,008 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $68,587 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $64,578 |
| Humalog Kwikpen U-100Insulin Lispro | 121 | $51,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $545 | $893,172642 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $52 | $340,836312 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $160 | $274,710221 claims |
| AstraZenecaFarxiga | $24,335 | $246,286251 claims |
| MerckJanuvia, Janumet Xr | $13 | $172,929160 claims |
| PfizerEliquis | $31 | $95,559117 claims |
| Johnson & JohnsonXarelto | $12 | $47,20345 claims |
| AbbVieLinzess | $287 | $40,09246 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $18,48121 claims |
| Antares Pharma, Inc.Xyosted | $43 | $14,01713 claims |
| Sanofi-aventis U.S. LLCLantus | $112 | $10,51252 claims |
| GSKAnoro Ellipta | $34 | $10,40914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.